Mavorixafor for Patients with Chronic Neutropenic Disorders Treated with G-CSF: Preliminary Response Data and G-CSF Dose Reduction in an Ongoing Phase 2, OpenLabel, Multicenter Study Support Reduction in G-CSF Dosing

被引：2

作者：

Warren, Julia T. ^{[1
,2
]}

Dickerson, Kathryn E. ^{[3
]}

Sharathkumar, Anjali A. ^{[4
]}

Walter, Jolan E. ^{[5
]}

Wilson, David B. ^{[6
]}

Adell, Katrina P. ^{[7
]}

Chen, Kelly ^{[7
]}

Dubuc, Susan ^{[7
]}

MacLeod, Rick ^{[7
]}

Peters, Katie ^{[7
]}

Stewart, Murray ^{[7
]}

Taveras, Arthur G. ^{[7
]}

Walkovich, Kelly ^{[8
]}

机构：

[1] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA

[2] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Div Hematol & Oncol, Dallas, TX 75390 USA

[4] Univ Iowa Hlth Care, Stead Family Dept Pediat, Carver Coll Med, Iowa City, IA USA

[5] Univ S Florida, Johns Hopkins All Childrens Hosp, Morsani Coll Med, Div Allergy & Immunol,Dept Pediat, St Petersburg, FL USA

[6] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA

[7] X4 Pharmaceut Inc, Boston, MA USA

[8] Univ Michigan, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173549

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[41] G-CSF increases hematological response and survival among patients with myelodysplasia treated with azacitidine
Falke, E.
Rossetti, J. M.
Shadduck, R. K.
Kaplan, R. B.
Kennedy, M.
Juvvadi, R.
Kramer, W.
Lister, J.
LEUKEMIA RESEARCH, 2007, 31 : S123 - S124
[42] G-CSF increases hematological response among patients with myelodysplasia treated with azacitidine.
Rossetti, James M.
Falke, Eric
Shadduck, Richard K.
Latsko, Joan M.
Kramer, Wendy
Lister, John
BLOOD, 2006, 108 (11) : 303B - 303B
[43] Large dose ifosfamide with cisplatin, etoposide and G-CSF in NSCLC: A phase II study
Constenla, M
Garcia-Arroyo, FR
Lorenzo, I
Rey, C
Carrete, N
ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
[44] Intermittent-low dose G-CSF treatment in a patient with chronic neutropenia
Yetgin, S
Ozbek, N
TURKISH JOURNAL OF PEDIATRICS, 1998, 40 (03) : 421 - 424
[45] Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF
Jindra, P
Koza, V
Lysák, D
Vozobulová, V
Steinerová, K
BONE MARROW TRANSPLANTATION, 2005, 35 (07) : 729 - 730
[46] Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF
Bone Marrow Transplantation, 2005, 35 : 729 - 730
[47] RESPONSE TO INDUCTION TREATMENT ADAPTED SELECTION OF MOBILIZATION REGIMEN IN MULTIPLE MYELOMA: THE G-CSF ALONE VERSUS HIGH-DOSE CYCLOPHOSPHAMIDE PLUS G-CSF REGIMEN
Lee, J. Y.
Kim, S. J.
Jang, J. E.
Suh, C.
Lee, H.
Yhim, H. Y.
Lee, W. S.
Min, C. K.
Lee, J. H.
Kim, J. S.
HAEMATOLOGICA, 2014, 99 : 647 - 648
[48] G-CSF alone is a mobilization therapy as effective as "CTX 4 gr/m2 plus G-CSF" in lymphoma patients not heavily pretreated - A prospective study
Leotta, S
Moschetti, G
Indelicato, F
Gioi, FL
Mercurio, S
Consoli, U
Di Raimondo, F
Milone, G
Giustolisi, R
BONE MARROW TRANSPLANTATION, 2002, 29 : S268 - S268
[49] A multicenter trial on stem cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus G-CSF or G-CSF alone for mobilization.
Bertolini, F
Lanza, A
Peccatori, F
Zibera, C
Gibelli, N
Perotti, C
Da Prada, GA
Pedrazzoli, P
Torretta, L
Martinelli, G
della Cuna, GR
BONE MARROW TRANSPLANTATION, 1998, 21 : S57 - S57
[50] Poor stem cell mobilisers - variation in response to G-CSF dose escalation
TCM Morris
L Ranaghan
M Drake
Bone Marrow Transplantation, 1999, 24 : 448 - 449

← 1 2 3 4 5 →